Business Wire

Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of Dry Eye Disease

BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases ...
The Motley Fool

Here's Why Ocular Therapeutix Stock Is Sinking Today

The company's experimental dry-eye treatment produced some disappointing clinical trial results. Ocular Therapeutix's only revenue-generating product, Dextenza, isn't making ends meet yet. Investors ...
Benzinga.com

Ocular Therapeutix™ Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA® (0.4 Dexamethasone Intracanalicular Insert for Ophthalmic Use) for the ...

Ocular Therapeutix™, Inc. OCUL, a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today ...